Haemonetics (NYSE: HAE) reported Q3 EPS of $1.19, $0.02 better than the analyst estimate of $1.17. Revenue for the quarter came in at $349 million versus the consensus estimate of $352.98 million.

GUIDANCE:

Haemonetics sees FY2025 EPS of $4.50-$4.70, versus the consensus of $4.59.

For earnings history and earnings-related data on Haemonetics (HAE) click here.